Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The FDA has approved Yeztugo, the first long-acting injectable PrEP shot, which could significantly impact HIV prevention ...